trial

Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects

NCTId NCT02174523
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 14 (actual)
Sponsored by Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Primary completion 2014-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
14 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2014-04
Primary completion
2014-04
Eligibility
MALE · 18 Years · 40 Years

Interventions & indications

Drugs
Lurasidone

Sponsors

Marubeni Pharmaceuticals (Suzhou) Co., Ltd.Lead Sponsor
Xuhui Central Hospital, ShanghaiCollaborator

Investigators

1
ChaoYing Hu, MDPrincipal Investigator

Sites

1 total
Shanghai, China

Facts & assertions

4 sourced
Enrollment
14
Phase
PHASE1
Primary Completion Date
2014-04
Status
COMPLETED
relationships
The graph out of here
drug
Lurasidone
drug
lead_sponsor
Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
company
collaborator
Xuhui Central Hospital, Shanghai
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
ChaoYing Hu, MD
person